Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women

J Endocrinol. 1976 Sep;70(3):421-8. doi: 10.1677/joe.0.0700421.

Abstract

Plasma levels of LH, FSH, prolactin, oestradiol and progesterone were determined daily during two consecutive menstrual cycles in six women volunteers. During the first (control) cycle no treatment was given and normal secretion of these hormones was observed. Oral administration of tamoxifen (20 mg/day), for either 5 or 10 days of the follicular phase of the second cycle, caused no change in either the overall length of the cycle or the time of occurrence of the mid-cycle gonadotrophin surge. There was little difference in the secretion of LH, FSH and progesterone during the control and test cycles. A two- to eight-fold increase in oestradiol levels was observed during test cycle which was most pronounced at the times of mid-cycle and mid-luteal hormone peaks. There was a significant decrease in plasma prolactin levels at mid-cycle but no real difference could be seen during the remainder of the cycle. The data suggest that tamoxifen may act directly on the ovary to stimulate oestradiol release without intermediary gonadotrophin stimulation. As the drug apparently inhibited prolactin secretion even in the presence of high oestradiol levels, an alternative explanation may be that the reduced prolactin concentration permits augmented ovarian stimulation by normal concentrations of gonadotrophins.

MeSH terms

  • Adult
  • Estradiol / blood*
  • Female
  • Follicle Stimulating Hormone / blood
  • Gonadotropins, Pituitary / blood*
  • Humans
  • Luteinizing Hormone / blood
  • Menstruation
  • Progesterone / blood*
  • Prolactin / blood
  • Stilbenes / pharmacology*
  • Tamoxifen / pharmacology*

Substances

  • Gonadotropins, Pituitary
  • Stilbenes
  • Tamoxifen
  • Progesterone
  • Estradiol
  • Prolactin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone